(3-bromo-phenyl)-[4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrimidin-2-yl]-amine | 915415-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (3-bromo-phenyl)-[4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrimidin-2-yl]-amine
• 英文别名: N-(3-bromophenyl)-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-amine
• CAS: 915415-04-2
• 化学式: C₁₇H₁₂BrN₅
• 分子量: 366.22
• InChiKey: UIWNMJOHEGQCKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Compounds and Compositions as Protein Kinase Inhibitors
  申请人：Okram Barun

  公开号：US20080300267A1

  公开（公告）日：2008-12-04

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the CDKs, Aurora, Jak2, Rock, CAMKII, FLT3, Tie2, TrkB, FGFR3 and KDR kinases.

  本发明提供了一种新型化合物类，包括该类化合物的制药组合物以及使用该类化合物治疗或预防与异常或非调节激酶活性相关的疾病或疾病的方法，特别是涉及CDKs、Aurora、Jak2、Rock、CAMKII、FLT3、Tie2、TrkB、FGFR3和KDR激酶异常激活的疾病或疾病。
• PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：IRM, LLC

  公开号：EP1896470A2

  公开（公告）日：2008-03-12
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS EN TANT QU'INHIBITEURS DE PROTEINE KINASE
  申请人：IRM LLC

  公开号：WO2006124863A2

  公开（公告）日：2006-11-23

  [EN] The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the CDKs, Aurora, Jak2, Rock, CAMKII, FLT3, Tie2, TrkB, FGFR3 and KDR kinases.
  [FR] L'invention concerne une nouvelle classe de composés, compositions pharmaceutiques comprenant de tels composés ainsi que des procédés d'utilisation pour traiter ou prévenir des maladies ou des troubles associés à l'activité anormale ou déréglée de la kinase, plus spécifiquement des maladies ou troubles mettant en oeuvre l'activation anormale de CDKs, Aurora, Jak2, Rock, CAMKII, FLT3, Tie2, TrkB, FGFR3 et KDR kinases.